Jones Hill Capital LP — 13F Holdings & Portfolio

CIK 2102314 · latest 13F-HR filed 2026-11-13

Jones Hill Capital LP manages $589.2M in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are BMRN (11.93%), BCRX (10.01%), TVTX (9.59%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 19 new positions and exited 15; 4 existing positions rose in reported value and 9 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$589.2M

Long-equity book

Holdings
33

Distinct positions

Period
2026-09-30

Filed 2026-11-13

Q/Q Activity
+19 / −15 / ↑4 / ↓9

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 71.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated May 6, 2026.

Assets Under Management
$642.4M
Discretionary
$642.4M
Employees
8
Accounts
8
Address
60 CHARLTON STREET
EIGHTH FLOOR SOUTH
NEW YORK, NY 10013
Phone
(212) 328-9320
Name Title / Status Ownership Type
GANDRUD, SOREN ALEXANDER, MAKRIYANNIS ControlCIO, LIMITED PARTNER
since Apr 2025
75% or moreIndividual
JHC MANAGER GP LLC ControlGENERAL PARTNER
since Apr 2025
Less than 5%Domestic Entity
MEEKINS, CHRISTOPHER, MARTIN ControlCCO, COO. GC, PARTNER
since Apr 2025
10–25%Individual
WALSH, TIMOTHY, FARLEY ControlCFO
since Nov 2025
Less than 5%Individual
GANDRUD, SOREN ALEXANDER, MAKRIYANNIS Control
Indirect owner via JHC MANAGER GP LLC
MANAGING MEMBER
since Apr 2025
50–75%Individual
Ownership & leadership changes · 1 filing with changes since Dec 5, 2025

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Dec 23, 2025 filing
  • ChangedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · title CIO, MANAGING PARTNER → CIO, LIMITED PARTNER
Dec 5, 2025 filing (earliest on record)
  • ListedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · MANAGING MEMBER · 50–75% · indirect via JHC MANAGER GP LLC · control person
  • ListedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · CIO, MANAGING PARTNER · 75% or more · control person
  • ListedJHC MANAGER GP LLC · GENERAL PARTNER · Less than 5% · control person
  • ListedMEEKINS, CHRISTOPHER, MARTIN · CCO, COO. GC, PARTNER · 10–25% · control person
  • ListedWALSH, TIMOTHY, FARLEY · CFO · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Jones Hill Capital LP Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $70.3M 11.93% 1,171,859 SH
2 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $59.0M 10.01% 7,083,300 SH
3 TRAVERE THERAPEUTICS INC TVTX 89422G107 $56.5M 9.59% 959,634 SH
4 INDIVIOR PHARMACEUTICALS INC SUPN 45579U109 $54.7M 9.29% 1,526,685 SH
5 PHARVARIS N V PHVS N69605108 $31.3M 5.32% 987,637 SH
6 CELCUITY INC CELC 15102K100 $30.4M 5.17% 382,901 SH
7 IONIS PHARMACEUTICALS INC IONS 462222100 $26.8M 4.55% 599,826 SH
8 SUPERNUS PHARMACEUTICALS SUPN 868459108 $25.9M 4.40% 601,685 SH
9 NUVATION BIO INC NUVB 67080N101 $25.1M 4.26% 4,486,986 SH
10 VERA THERAPEUTICS INC VERA 92337R101 $21.1M 3.57% 652,218 SH
11 TREVI THERAPEUTICS INC TRVI 89532M101 $20.7M 3.52% 1,447,156 SH
12 BICARA THERAPEUTICS INC BCAX 055477103 $19.8M 3.36% 1,064,233 SH
13 RELMADA THERAPEUTICS INC RLMD 75955J402 $19.7M 3.35% 5,237,628 SH
14 ABIVAX SA ABVX 00370M103 $14.1M 2.40% 142,558 SH
15 ACLARIS THERAPEUTICS INC ACRS 00461U105 $13.2M 2.24% 2,504,651 SH
16 INSMED INC INSM 457669307 $12.2M 2.06% 106,528 SH
17 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $11.8M 2.01% 83,426 SH
18 IMMUNOCORE HLDGS PLC IMCR 45258D105 $11.6M 1.98% 384,278 SH
19 ERASCA INC ERAS 29479A108 $8.9M 1.52% 610,118 SH
20 CAPRICOR THERAPEUTICS INC CAPR 14070B309 $8.5M 1.43% 892,532 SH
21 DIANTHUS THERAPEUTICS INC DNTH 252828108 $7.0M 1.20% 80,017 SH
22 NEUROGENE INC NGNE 64135M105 $6.1M 1.03% 217,700 SH
23 CORBUS PHARMACEUTICALS HLDGS CRBP 21833P301 $6.0M 1.03% 886,428 SH
24 TONIX PHARMACEUTICALS HLDG C TNXP 890260839 $5.5M 0.93% 563,739 SH
25 SAGIMET BIOSCIENCES INC SGMT 786700104 $5.0M 0.84% 502,587 SH
26 DYNE THERAPEUTICS INC DYN 26818M108 $4.8M 0.82% 300,900 SH
27 AVALYN PHARMACEUTICALS INC AVLN 05348Y105 $3.6M 0.61% 126,744 SH
28 ATTOVIA THERAPEUTICS INC ATTO 04987L102 $3.1M 0.53% 182,295 SH
29 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $2.0M 0.34% 276,830 SH
30 LEXEO THERAPEUTICS INC LXEO 52886X107 $2.0M 0.34% 593,737 SH
31 OLEMA PHARMACEUTICALS INC OLMA 68062P106 $1.8M 0.30% 206,397 SH
32 TENAX THERAPEUTICS INC TENX 88032L605 $230.9K 0.04% 122,169 SH
33 ALVOTECH ALVO L01800108 $154.9K 0.03% 26,700 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-13 $589.2M 33 0002102314-26-000006
2026-06-30 2026-08-13 $470.4M 29 0002102314-26-000005
2026-03-31 2026-05-14 $466.5M 26 0002102314-26-000003
Filer Information
Address
60 CHARLTON STREET
EIGHTH FLOOR SOUTH
NEW YORK, NY 10013
Phone
(212) 328-9320
Filing Manager
Jones Hill Capital LP
NEW YORK, NY
Signatory
Christopher Martin Meekins
CCO, COO, GC, Partner